Supernjus FDA OKs ONAPGO™ (apomorphine hydrochloride) for Parkinson’s

 

• ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease
• ONAPGO is a wearable subcutaneous infusion device that provides continuous treatment during the waking day for more consistent control of OFF time
• ONAPGO will be available in the U.S. in second quarter 2025

https://www.globenewswire.com/news-release/2025/02/04/3020423/19871/en/Supernus-Announces-FDA-Approval-of-ONAPGO-apomorphine-hydrochloride-for-Parkinson-s-Disease.html